Ipidacrine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ipidacrine (Neiromidin) is a novel substance synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound contains the structure of 4-aminopyridine and is structurally very similar to tacrine.[1]
Ipidacrine is a reversible acetylcholinesterase inhibitor used in memory disorders of different origins.[2][3][4]
Ipidacrine directly stimulates impulse transmission in the CNS and neuromuscular synapses by blocking membrane potassium channels. Neiromidin enhances not only choline, but also adrenaline, serotonin, histamine and oxytocin effects on smooth muscle.[5]
References
- ↑ Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio (1998). “Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent”. CNS Drug Reviews. 4 (3): 247. doi:10.1111/j.1527-3458.1998.tb00067.x.
- ↑ Damulin, IV; Stepkina, DA; Lokshina, AB (2011). “Neuromidin in mixed vascular and Alzheimer’s dementia”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (2): 40–3. PMID 21350422.
- ↑ Pustokhanova, LV; Morozova, EM (2011). “Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (4 Pt 2): 23–7. PMID 23120773.
- ↑ Onodera, K; Kojima, J; Wachi, M (1998). “Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task”. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. 18 (2): 33–7. PMID 9656230.
- ↑ Neiromidin Product Information
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
